US appeals court revives GlaxoSmithKline verdict against Teva

A federal appeals court on Friday reinstated a 2017 jury verdict that required Teva Pharmaceutical Industries Ltd to pay GlaxoSmithKline Plc more than $235 million for infringing a patent for its blood pressure drug Coreg.

The 2-1 decision was issued by the US Federal Circuit Court of Appeals in Washington, DC.
Subscribe for our daily newsletter
Subscribe for our daily newsletter

By subscribing I accept the terms of use and privacy policy